Cargando…

Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor

Raising functional antibodies against G protein-coupled receptors (GPCRs) is challenging due to their low density expression, instability in the absence of the cell membrane's lipid bilayer and frequently short extracellular domains that can serve as antigens. In addition, a particular therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Könitzer, Jennifer D., Pramanick, Shreya, Pan, Qi, Augustin, Robert, Bandholtz, Sebastian, Harriman, William, Izquierdo, Shelley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384726/
https://www.ncbi.nlm.nih.gov/pubmed/28055305
http://dx.doi.org/10.1080/19420862.2016.1276683
_version_ 1782520491818352640
author Könitzer, Jennifer D.
Pramanick, Shreya
Pan, Qi
Augustin, Robert
Bandholtz, Sebastian
Harriman, William
Izquierdo, Shelley
author_facet Könitzer, Jennifer D.
Pramanick, Shreya
Pan, Qi
Augustin, Robert
Bandholtz, Sebastian
Harriman, William
Izquierdo, Shelley
author_sort Könitzer, Jennifer D.
collection PubMed
description Raising functional antibodies against G protein-coupled receptors (GPCRs) is challenging due to their low density expression, instability in the absence of the cell membrane's lipid bilayer and frequently short extracellular domains that can serve as antigens. In addition, a particular therapeutic concept may require an antibody to not just bind the receptor, but also act as a functional receptor agonist or antagonist. Antagonizing the glucose-dependent insulinotropic polypeptide (GIP) receptor may open up new therapeutic modalities in the treatment of diabetes and obesity. As such, a panel of monoclonal antagonistic antibodies would be a useful tool for in vitro and in vivo proof of concept studies. The receptor is highly conserved between rodents and humans, which has contributed to previous mouse and rat immunization campaigns generating very few usable antibodies. Switching the immunization host to chicken, which is phylogenetically distant from mammals, enabled the generation of a large and diverse panel of monoclonal antibodies containing 172 unique sequences. Three-quarters of all chicken-derived antibodies were functional antagonists, exhibited high-affinities to the receptor extracellular domain and sampled a broad epitope repertoire. For difficult targets, including GPCRs such as GIPR, chickens are emerging as valuable immunization hosts for therapeutic antibody discovery.
format Online
Article
Text
id pubmed-5384726
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-53847262017-04-12 Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor Könitzer, Jennifer D. Pramanick, Shreya Pan, Qi Augustin, Robert Bandholtz, Sebastian Harriman, William Izquierdo, Shelley MAbs Reports Raising functional antibodies against G protein-coupled receptors (GPCRs) is challenging due to their low density expression, instability in the absence of the cell membrane's lipid bilayer and frequently short extracellular domains that can serve as antigens. In addition, a particular therapeutic concept may require an antibody to not just bind the receptor, but also act as a functional receptor agonist or antagonist. Antagonizing the glucose-dependent insulinotropic polypeptide (GIP) receptor may open up new therapeutic modalities in the treatment of diabetes and obesity. As such, a panel of monoclonal antagonistic antibodies would be a useful tool for in vitro and in vivo proof of concept studies. The receptor is highly conserved between rodents and humans, which has contributed to previous mouse and rat immunization campaigns generating very few usable antibodies. Switching the immunization host to chicken, which is phylogenetically distant from mammals, enabled the generation of a large and diverse panel of monoclonal antibodies containing 172 unique sequences. Three-quarters of all chicken-derived antibodies were functional antagonists, exhibited high-affinities to the receptor extracellular domain and sampled a broad epitope repertoire. For difficult targets, including GPCRs such as GIPR, chickens are emerging as valuable immunization hosts for therapeutic antibody discovery. Taylor & Francis 2017-01-05 /pmc/articles/PMC5384726/ /pubmed/28055305 http://dx.doi.org/10.1080/19420862.2016.1276683 Text en © 2017 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Reports
Könitzer, Jennifer D.
Pramanick, Shreya
Pan, Qi
Augustin, Robert
Bandholtz, Sebastian
Harriman, William
Izquierdo, Shelley
Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor
title Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor
title_full Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor
title_fullStr Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor
title_full_unstemmed Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor
title_short Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor
title_sort generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the gip receptor
topic Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384726/
https://www.ncbi.nlm.nih.gov/pubmed/28055305
http://dx.doi.org/10.1080/19420862.2016.1276683
work_keys_str_mv AT konitzerjenniferd generationofahighlydiversepanelofantagonisticchickenmonoclonalantibodiesagainstthegipreceptor
AT pramanickshreya generationofahighlydiversepanelofantagonisticchickenmonoclonalantibodiesagainstthegipreceptor
AT panqi generationofahighlydiversepanelofantagonisticchickenmonoclonalantibodiesagainstthegipreceptor
AT augustinrobert generationofahighlydiversepanelofantagonisticchickenmonoclonalantibodiesagainstthegipreceptor
AT bandholtzsebastian generationofahighlydiversepanelofantagonisticchickenmonoclonalantibodiesagainstthegipreceptor
AT harrimanwilliam generationofahighlydiversepanelofantagonisticchickenmonoclonalantibodiesagainstthegipreceptor
AT izquierdoshelley generationofahighlydiversepanelofantagonisticchickenmonoclonalantibodiesagainstthegipreceptor